The short answer
On 1 April 2013 the Supreme Court of India confirmed the rejection of Novartis's patent application for the beta crystalline form of imatinib mesylate (Glivec). The court held that the claimed form was a modification of a known substance and did not qualify as an invention under section 3(d) of the Patents Act.
Case snapshot
| Item | Detail |
|---|---|
| Court | Supreme Court of India (two-judge bench; Justice Aftab Alam wrote the judgment) |
| Case numbers | Civil Appeals 2706-2716, 2717-2727 and 2728 of 2013 |
| Decided | 1 April 2013 |
| Parties | Novartis AG v Union of India and others |
| IP area | Patent: section 3(d), pharmaceutical forms |
| Result | Rejection of the patent application confirmed |
Background and facts
Novartis applied for an Indian patent on the beta crystalline form of imatinib mesylate, the active substance of the cancer drug Glivec. The basic imatinib compound had been disclosed in a 1993 patent application and in scientific articles.
The application was rejected by the Indian Patent Office. The Madras High Court had held that section 3(d) does not violate Article 14 (equality) of the Constitution, and Novartis did not appeal that ruling. The Intellectual Property Appellate Board then rejected the application under section 3(d), and Novartis went to the Supreme Court by special leave.
The legal question
Does the claimed beta crystalline form of imatinib mesylate qualify as an invention, or is it a new form of a known substance that must show enhanced efficacy to be patentable under section 3(d) of the Indian Patents Act?
The court's reasoning
- Section 3(d) excludes new forms of a known substance unless they differ significantly in efficacy.
- The court found the claimed form was a modification of a known drug and did not meet the section 3(d) test.
- It took care to note that the application was filed during a time of transition in Indian patent law, so the ruling is narrow.
Commentators have debated the court's reading of "efficacy". Some argue that the narrowest reading, which the courts adopted, is the one least consistent with the stated aim of stopping "evergreening". We summarise the reasoning from secondary sources and did not read the full judgment.
Result and outcome
The Supreme Court confirmed the rejection by the Patent Office, so Novartis did not obtain an Indian patent for that form of Glivec.
Analysis: why this case matters
The judgment is a reference point for pharmaceutical patent policy in developing countries. It shows how a country can use its own patentability rules to limit follow-on patents on new forms of known drugs.
For Bangladesh, where the Patent Act 2023 and pharmaceutical flexibilities matter, the case is a useful comparison for how national law can shape pharmaceutical patents.
Practical lessons for brand owners and inventors
- Draft claims with data that show real improvement over the known substance.
- Study each country's patentability exclusions before filing follow-on patents.
- Keep evidence of therapeutic effect (comparative studies) ready for examination.
- Assess the policy and litigation risk of pharmaceutical patent strategy country by country.
Sources and further reading
UNCTAD IP case law: Novartis AG v. Union of India (1 April 2013)
Nishith Desai Associates: Novartis judgment note
Wikipedia: Novartis v. Union of India and Others
This study is built from the sources listed above. Where a point comes from a secondary report rather than the judgment itself, we say so. Check the judgment before relying on any detail.
Questions and answers
What did the Supreme Court decide?
That the beta crystalline form of imatinib mesylate was not patentable under section 3(d).
When?
On 1 April 2013.
Does the ruling ban all pharmaceutical patents in India?
No, it is a narrow decision about a new form of a known substance.
Facing a similar dispute?
SUPREMEiP® prepares the evidence and works with local counsel for registration, watch and enforcement.
